• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Diwan Anil gifted 94,471 shares, closing all direct ownership in the company

    8/10/22 6:51:52 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NNVC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Diwan Anil

    (Last) (First) (Middle)
    C/O NANOVIRICIDES, INC.,
    1 CONTROL DRIVE

    (Street)
    SHELTON CT 06484

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NANOVIRICIDES, INC. [ NNVC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President
    3. Date of Earliest Transaction (Month/Day/Year)
    08/08/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.001 per share 08/08/2022 G(1) 94,471 D $0 0(2)(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reported transaction involves a gift made by the reporting person for estate planning purposes to an irrevocable trust whose beneficiaries are his minor children and of which he is neither the trustee nor a beneficiary.
    2. Does not include 6,074 shares of Series A Convertible Preferred Stock (the "Series A Stock") owned by the reporting person which is convertible into three and one-half shares of common stock upon limited conditions.
    3. Does not include 200,000 shares of Series A Stock or 470,959 shares of common stock owned by TheraCour Pharma, Inc., over which the reporting person holds voting and dispositive power.
    /s/ Anil Diwan 08/10/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NNVC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NNVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NNVC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

    SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.Event Information:EventNanoViricides Presentation at the Biotech Showcase, San FransiscoDay & DateTuesday, January 14, 2025Time, Track & Room2:30pm PT, Yosemite A (Ballroom Level)LocationHilton San Fransisco - Union SquareAnil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline a

    1/13/25 6:30:00 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

    SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already.This season, two different genotypes of H5N1 bird flu, namely (a) the severe and lethal form D1.1 that has spread globally in birds, and (b) the less severe B3.13 genotype widely spread in diary cattle in North America are causing major concerns even as Seasonal Influenza cases abound.In addition to that, in the USA, and globally, there are significant numbers of cases of COVID-19, RSV, and hMPV as expected seasonally, that cause various respiratory syndromes from common colds

    1/8/25 6:30:00 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

    SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug."Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."WHO has stated "Available virus

    12/23/24 6:30:00 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NNVC
    SEC Filings

    View All

    SEC Form 10-Q filed by NanoViricides Inc.

    10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)

    5/15/25 4:31:12 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NanoViricides Inc.

    10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)

    2/14/25 4:30:24 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NanoViricides Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - NANOVIRICIDES, INC. (0001379006) (Filer)

    12/12/24 5:00:49 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NNVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by 10% Owner before reverse split Boniuk Milton

    4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

    1/28/25 3:36:56 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by 10% Owner before reverse split Stephenson Fournier, Pllc

    4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

    1/24/25 11:58:54 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Diwan Anil gifted 94,471 shares, closing all direct ownership in the company

    4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

    8/10/22 6:51:52 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NNVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - NANOVIRICIDES, INC. (0001379006) (Subject)

    2/16/21 9:47:52 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care